TMOD3 drives malignant progression in pancreatic cancer through physical interaction with LRRFIP1

Pancreatic cancer is a disease that moves with terrifying speed. By the time it is found, it has often already spread, making it one of the most difficult cancers to treat. Because the disease is so aggressive, scientists are constantly searching for the specific molecular switches that tell cancer cells to grow and spread. One such switch involves the internal skeleton of a cell. Just as our bones give our bodies shape and allow us to move, cells have their own internal framework made of tiny protein fibers called actin. These fibers constantly rearrange themselves to help cells change shape, crawl, and invade new territory. Proteins that manage this framework are critical; if they malfunction, a cell might lose its ability to stay put and begin to wander, which is the first step toward cancer spreading to other organs.

In a new study, researchers have identified a specific protein called TMOD3 that acts as a powerful driver of this dangerous behavior in pancreatic cancer. The team, led by scientists at The First Hospital of Jiaxing in China, discovered that this protein is found in much higher amounts in pancreatic tumors than in healthy tissue. More importantly, they found that the more of this protein a patient has, the shorter their life expectancy tends to be. The researchers did not stop at simply finding the protein; they wanted to know exactly how it works. They traced its actions to a partnership with another protein called LRRFIP1. Through a series of experiments in the lab and in mice, they showed that TMOD3 physically grabs onto LRRFIP1, and together, this pair forces the cancer cells to multiply rapidly and spread to the lungs. When the researchers blocked this partnership, the cancer's ability to grow and spread was significantly reduced.

To understand the role of TMOD3, the scientists first looked at data from thousands of patients. They compared the genetic activity of pancreatic tumors against healthy tissue and found that the gene for TMOD3 was turned on much higher in the cancer. They confirmed this by examining actual tissue samples from 79 patients. Under a microscope, the cancerous tissue glowed with the presence of TMOD3, while the healthy tissue next to it showed very little. The researchers then linked this finding to patient outcomes. They found that patients with high levels of TMOD3 in their tumors did not survive as long as those with low levels. This suggested that TMOD3 was not just a bystander but an active participant in making the disease worse.

To prove that TMOD3 was actually causing the cancer to grow, the team moved to the laboratory. They took pancreatic cancer cells and used a technique to silence the gene for TMOD3, effectively turning it off. In the petri dishes, the cells without TMOD3 stopped growing as fast. They also lost their ability to move. The researchers tested this by creating a scratch in a layer of cells and watching how quickly they moved to fill the gap. The cells with normal levels of TMOD3 rushed to close the gap, but the cells with TMOD3 turned off moved very slowly. They also tested how well the cells could invade through a barrier, a process that mimics how cancer spreads through tissue. Again, removing TMOD3 made the cells much less aggressive.

The team then took these findings into living animals to see if the results held up in a more complex system. They injected pancreatic cancer cells into mice. One group of mice received cells with normal TMOD3 levels, while another group received cells where TMOD3 had been silenced. The mice with normal cells developed large tumors quickly. In contrast, the mice with the silenced cells developed much smaller tumors. The researchers also tested how well the cancer spread to the lungs, a common site for pancreatic cancer metastasis. They injected cells directly into the bloodstream of the mice. The mice with normal TMOD3 levels developed many large nodules in their lungs. The mice with silenced TMOD3 had far fewer and smaller nodules. These experiments confirmed that TMOD3 is essential for the cancer to grow and spread in a living body.

Having established that TMOD3 drives the cancer, the researchers asked how it does it. Proteins rarely work alone; they usually interact with other proteins to get things done. Using computer models and laboratory tests, the team discovered that TMOD3 physically binds to a protein called LRRFIP1. This interaction is like two hands clasping together. The researchers checked if TMOD3 was simply telling the cell to make more LRRFIP1, but they found that the amount of LRRFIP1 remained the same whether TMOD3 was present or not. Instead, TMOD3 seems to need LRRFIP1 to function. When the researchers silenced LRRFIP1 in the cancer cells, the harmful effects of TMOD3 disappeared. The cells stopped growing fast and stopped invading, even if TMOD3 was still present. This proved that TMOD3 relies entirely on its partnership with LRRFIP1 to cause damage.

The study concludes that the connection between TMOD3 and LRRFIP1 is a critical pathway that pancreatic cancer uses to become deadly. The researchers showed that this protein pair is a major reason why these tumors grow so fast and spread so easily. By blocking this interaction, it might be possible to slow down the disease. While the study did not test a new drug, it identified a specific target for future treatments. If scientists can develop a way to stop TMOD3 from grabbing onto LRRFIP1, they might be able to stop the cancer from spreading without harming the rest of the body. This discovery offers a new hope for understanding the mechanics of pancreatic cancer and points toward a potential strategy for treating it.